Addex Therapeutics Ltd (ADXN) Stock Overview
Explore Addex Therapeutics Ltd’s financial performance, market position, analyst ratings, and future outlook.
Addex Therapeutics Ltd (ADXN)
Key Financials
Key Financials
Market Cap
6.1M
P/E Ratio
-0.57
EPS (TTM)
$-6.30
ROE
-1.31%
ADXN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Addex Therapeutics Ltd (NASDAQ: ADXN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Addex Therapeutics Ltd's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ADXN on the NASDAQ shows an RSI of 36.09, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.98 for the NASDAQ listing.
Key metrics behind Addex Therapeutics Ltd's NASDAQ-traded stock include a P/E ratio of -0.57 and a market capitalization of 6.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ADXN on the NASDAQ.